Phreesia (NYSE:PHR) Director Michael Weintraub Sells 10,680 Shares

Phreesia (NYSE:PHR) Director Michael Weintraub sold 10,680 shares of Phreesia stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $32.51, for a total value of $347,206.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Michael Weintraub also recently made the following trade(s):

  • On Monday, February 10th, Michael Weintraub sold 15,177 shares of Phreesia stock. The stock was sold at an average price of $32.79, for a total value of $497,653.83.

Shares of NYSE PHR opened at $32.61 on Friday. Phreesia has a 12-month low of $22.05 and a 12-month high of $34.39. The company has a debt-to-equity ratio of 0.21, a current ratio of 4.01 and a quick ratio of 4.01. The stock’s 50 day simple moving average is $28.93 and its 200 day simple moving average is $27.71.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Tuesday, December 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. The company had revenue of $32.80 million during the quarter, compared to the consensus estimate of $29.48 million. Phreesia’s revenue for the quarter was up 32.3% on a year-over-year basis. Sell-side analysts expect that Phreesia will post -0.43 earnings per share for the current year.

Several research analysts have recently commented on PHR shares. Raymond James started coverage on Phreesia in a research report on Thursday, December 19th. They issued an “outperform” rating and a $33.00 target price for the company. KeyCorp started coverage on Phreesia in a research report on Thursday, January 30th. They issued an “overweight” rating and a $36.00 target price for the company. ValuEngine lowered Phreesia from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Zacks Investment Research lowered Phreesia from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Cantor Fitzgerald started coverage on Phreesia in a research report on Wednesday, January 8th. They issued an “overweight” rating and a $32.00 target price for the company. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Phreesia currently has a consensus rating of “Buy” and a consensus price target of $31.78.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Altshuler Shaham Ltd bought a new stake in Phreesia during the 4th quarter valued at $29,000. Bank of Montreal Can bought a new stake in Phreesia during the 4th quarter valued at $33,000. Victory Capital Management Inc. bought a new stake in Phreesia during the 4th quarter valued at $53,000. Russell Investments Group Ltd. bought a new stake in Phreesia during the 3rd quarter valued at $47,000. Finally, Citigroup Inc. raised its stake in Phreesia by 339.2% during the 4th quarter. Citigroup Inc. now owns 2,073 shares of the company’s stock valued at $55,000 after acquiring an additional 1,601 shares in the last quarter. 51.49% of the stock is currently owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

Recommended Story: Purposes and Functions of the Federal Reserve

Insider Buying and Selling by Quarter for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.